Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer

In Rae Cho, Jun Chul Park, Chan Hyuk Park, Jung Hyun Jo, Hyun Jik Lee, Sunyong Kim, Choong Nam Shim, Hyuk Lee, Sung Kwan Shin, SangKil Lee, Yongchan Lee

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: Several studies have shown that the neutrophil to lymphocyte ratio (NLR) in peripheral blood is a prognostic factor of various cancers. However, there is limited information on the clinical and prognostic significance of NLR in patients with metastatic advanced gastric cancer (AGC). Therefore, we examined whether the NLR can be used as a prognostic marker for predicting chemotherapeutic response and survival outcomes in metastatic AGC patients who are receiving palliative chemotherapy.

Method: A total of 268 patients diagnosed with metastatic AGC were enrolled. NLR was calculated from complete blood cell count taken before the first chemotherapy treatment. Patients were divided into two groups according to the median value of NLR: a high NLR group and a low NLR group.

Result: The median follow-up period was 340 days (range 72–1796 days) and median NLR was 3.06 (range 0.18–18.16). The high NLR group (NLR >3.0) contained 138 patients and the low NLR group (NLR ≤3.0) contained 130 patients. Low NLR group patients had a significantly higher chemotherapeutic disease control rate (90.0 % vs. 80.4; P = 0.028), and longer progression-free survival (PFS) and overall survival (OS) than the high NLR group patients (186 vs. 146 days; P = 0.001; 414 vs. 280 days; P < 0.001, respectively). In multivariate analysis, NLR showed a significant association with PFS (HR 1.478; 95 % CI 1.154–1.892; P = 0.002) and OS (HR 1.569; 95 % CI 1.227–2.006; P < 0.001).

Conclusion: Pretreatment NLR is a useful prognostic marker in patients with metastatic AGC who are undergoing palliative chemotherapy.

Original languageEnglish
Pages (from-to)703-710
Number of pages8
JournalGastric Cancer
Volume17
Issue number4
DOIs
Publication statusPublished - 2014 Sep 20

Fingerprint

Stomach Neoplasms
Neutrophils
Lymphocytes
Survival
Therapeutics
Blood Cell Count
Drug Therapy
Disease-Free Survival
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Cho, In Rae ; Park, Jun Chul ; Park, Chan Hyuk ; Jo, Jung Hyun ; Lee, Hyun Jik ; Kim, Sunyong ; Shim, Choong Nam ; Lee, Hyuk ; Shin, Sung Kwan ; Lee, SangKil ; Lee, Yongchan. / Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. In: Gastric Cancer. 2014 ; Vol. 17, No. 4. pp. 703-710.
@article{12514e5f201745f193a1b50fb45e3f1d,
title = "Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer",
abstract = "Background: Several studies have shown that the neutrophil to lymphocyte ratio (NLR) in peripheral blood is a prognostic factor of various cancers. However, there is limited information on the clinical and prognostic significance of NLR in patients with metastatic advanced gastric cancer (AGC). Therefore, we examined whether the NLR can be used as a prognostic marker for predicting chemotherapeutic response and survival outcomes in metastatic AGC patients who are receiving palliative chemotherapy.Method: A total of 268 patients diagnosed with metastatic AGC were enrolled. NLR was calculated from complete blood cell count taken before the first chemotherapy treatment. Patients were divided into two groups according to the median value of NLR: a high NLR group and a low NLR group.Result: The median follow-up period was 340 days (range 72–1796 days) and median NLR was 3.06 (range 0.18–18.16). The high NLR group (NLR >3.0) contained 138 patients and the low NLR group (NLR ≤3.0) contained 130 patients. Low NLR group patients had a significantly higher chemotherapeutic disease control rate (90.0 {\%} vs. 80.4; P = 0.028), and longer progression-free survival (PFS) and overall survival (OS) than the high NLR group patients (186 vs. 146 days; P = 0.001; 414 vs. 280 days; P < 0.001, respectively). In multivariate analysis, NLR showed a significant association with PFS (HR 1.478; 95 {\%} CI 1.154–1.892; P = 0.002) and OS (HR 1.569; 95 {\%} CI 1.227–2.006; P < 0.001).Conclusion: Pretreatment NLR is a useful prognostic marker in patients with metastatic AGC who are undergoing palliative chemotherapy.",
author = "Cho, {In Rae} and Park, {Jun Chul} and Park, {Chan Hyuk} and Jo, {Jung Hyun} and Lee, {Hyun Jik} and Sunyong Kim and Shim, {Choong Nam} and Hyuk Lee and Shin, {Sung Kwan} and SangKil Lee and Yongchan Lee",
year = "2014",
month = "9",
day = "20",
doi = "10.1007/s10120-013-0330-2",
language = "English",
volume = "17",
pages = "703--710",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "4",

}

Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. / Cho, In Rae; Park, Jun Chul; Park, Chan Hyuk; Jo, Jung Hyun; Lee, Hyun Jik; Kim, Sunyong; Shim, Choong Nam; Lee, Hyuk; Shin, Sung Kwan; Lee, SangKil; Lee, Yongchan.

In: Gastric Cancer, Vol. 17, No. 4, 20.09.2014, p. 703-710.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer

AU - Cho, In Rae

AU - Park, Jun Chul

AU - Park, Chan Hyuk

AU - Jo, Jung Hyun

AU - Lee, Hyun Jik

AU - Kim, Sunyong

AU - Shim, Choong Nam

AU - Lee, Hyuk

AU - Shin, Sung Kwan

AU - Lee, SangKil

AU - Lee, Yongchan

PY - 2014/9/20

Y1 - 2014/9/20

N2 - Background: Several studies have shown that the neutrophil to lymphocyte ratio (NLR) in peripheral blood is a prognostic factor of various cancers. However, there is limited information on the clinical and prognostic significance of NLR in patients with metastatic advanced gastric cancer (AGC). Therefore, we examined whether the NLR can be used as a prognostic marker for predicting chemotherapeutic response and survival outcomes in metastatic AGC patients who are receiving palliative chemotherapy.Method: A total of 268 patients diagnosed with metastatic AGC were enrolled. NLR was calculated from complete blood cell count taken before the first chemotherapy treatment. Patients were divided into two groups according to the median value of NLR: a high NLR group and a low NLR group.Result: The median follow-up period was 340 days (range 72–1796 days) and median NLR was 3.06 (range 0.18–18.16). The high NLR group (NLR >3.0) contained 138 patients and the low NLR group (NLR ≤3.0) contained 130 patients. Low NLR group patients had a significantly higher chemotherapeutic disease control rate (90.0 % vs. 80.4; P = 0.028), and longer progression-free survival (PFS) and overall survival (OS) than the high NLR group patients (186 vs. 146 days; P = 0.001; 414 vs. 280 days; P < 0.001, respectively). In multivariate analysis, NLR showed a significant association with PFS (HR 1.478; 95 % CI 1.154–1.892; P = 0.002) and OS (HR 1.569; 95 % CI 1.227–2.006; P < 0.001).Conclusion: Pretreatment NLR is a useful prognostic marker in patients with metastatic AGC who are undergoing palliative chemotherapy.

AB - Background: Several studies have shown that the neutrophil to lymphocyte ratio (NLR) in peripheral blood is a prognostic factor of various cancers. However, there is limited information on the clinical and prognostic significance of NLR in patients with metastatic advanced gastric cancer (AGC). Therefore, we examined whether the NLR can be used as a prognostic marker for predicting chemotherapeutic response and survival outcomes in metastatic AGC patients who are receiving palliative chemotherapy.Method: A total of 268 patients diagnosed with metastatic AGC were enrolled. NLR was calculated from complete blood cell count taken before the first chemotherapy treatment. Patients were divided into two groups according to the median value of NLR: a high NLR group and a low NLR group.Result: The median follow-up period was 340 days (range 72–1796 days) and median NLR was 3.06 (range 0.18–18.16). The high NLR group (NLR >3.0) contained 138 patients and the low NLR group (NLR ≤3.0) contained 130 patients. Low NLR group patients had a significantly higher chemotherapeutic disease control rate (90.0 % vs. 80.4; P = 0.028), and longer progression-free survival (PFS) and overall survival (OS) than the high NLR group patients (186 vs. 146 days; P = 0.001; 414 vs. 280 days; P < 0.001, respectively). In multivariate analysis, NLR showed a significant association with PFS (HR 1.478; 95 % CI 1.154–1.892; P = 0.002) and OS (HR 1.569; 95 % CI 1.227–2.006; P < 0.001).Conclusion: Pretreatment NLR is a useful prognostic marker in patients with metastatic AGC who are undergoing palliative chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84919399351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919399351&partnerID=8YFLogxK

U2 - 10.1007/s10120-013-0330-2

DO - 10.1007/s10120-013-0330-2

M3 - Article

C2 - 24442663

AN - SCOPUS:84919399351

VL - 17

SP - 703

EP - 710

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 4

ER -